Cellectar Biosciences Secures Multi-Year Supply Agreement for Alpha-Emitting Radioisotopes to Advance Targeted Cancer Therapies
核心洞察
Cellectar Biosciences announced a strategic multi-year supply agreement with Ionetix Corporation for clinical and commercial-scale production of Actinium-225 and Astatine-211 radioisotopes.
The agreement supports development of CLR-225 (搜索), a phospholipid radioconjugate targeting challenging solid tumors including pancreatic cancer, advancing the company's targeted alpha therapy pipeline.
Ionetix is installing a second cyclotron at its Michigan facility to meet growing demand, with dedicated production lines for each alpha-emitting isotope.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has announced a strategic multi-year supply agreement with Ionetix Corporation to secure reliable access to two critical alpha-emitting radioisotopes: Actinium-225 (Ac-225) and Astatine-211 (At-211). The partnership positions the late-stage clinical biopharmaceutical company to advance its targeted alpha therapy (TAT) pipeline, particularly the development of CLR-225 (搜索) for solid tumor treatment.
Strategic Supply Partnership Addresses Critical Manufacturing Need
Under the agreement, Ionetix will provide Cellectar with clinical and commercial-scale supply of cGMP-grade Ac-225 and At-211 to support drug development programs through clinical trials and potential commercial launches. The collaboration addresses a fundamental challenge in radiopharmaceutical development: securing consistent, high-quality isotope supply for therapeutic applications.
"As we prepare for the future expansion of Cellectar's radiotherapeutic pipeline beyond our beta and Auger emitter clinical programs and work to advance CLR-225 (搜索) into clinical trials as a potential treatment for challenging solid tumor cancers such as pancreatic cancer, establishing a dependable and fully scalable supply of high-quality alpha-emitting isotopes is essential for the development of our targeted PRC pipeline," said Jarrod Longcor, chief operating officer of Cellectar Biosciences.
Expanding Manufacturing Capacity for Alpha Therapies
Ionetix is currently installing a second cyclotron at its Michigan facility, creating dedicated production capabilities for each isotope. The expanded infrastructure will house two cyclotrons on-site—one dedicated to commercial-scale Ac-225 production and the other for At-211 production.
"We are excited to collaborate with Cellectar to support their mission to deliver life-extending therapies for cancer patients," said David Eve, vice president of medical affairs at Ionetix. "Our cyclotron-based platform is designed to meet the growing demand for Ac-225 and the rapidly emerging need for At-211—both essential to advancing Cellectar's next-generation TATs."
Proprietary Platform Technology Enables Targeted Delivery
Cellectar's proprietary phospholipid ether platform technology has demonstrated robust delivery of various isotopes directly to tumor cells across a broad range of cancers. This unique capability allows the company to identify optimal isotopes for specific tumor types. When paired with the platform, Ac-225 and At-211 are designed to deposit highly localized, high-energy radiation that can destroy tumors while sparing surrounding healthy tissue.
The company's core objective centers on leveraging its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop next-generation cancer cell-targeting treatments that deliver improved efficacy and better safety profiles.
Focus on Challenging Solid Tumors
The supply agreement specifically supports development of phospholipid radioconjugate (PRC) CLR-225 (搜索), which targets challenging solid tumor cancers including pancreatic cancer. This represents an expansion of Cellectar's radiotherapeutic pipeline beyond current beta and Auger emitter clinical programs, positioning the company to address significant unmet medical needs in oncology.